Nymox Pharmaceutical Corporation (NYMXF)

Nymox Pharmaceutical Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year	2022	2021	2020	2019	2018
Cash & Equivalents	1.4	0.83	3.61	5.24	7.95
Cash & Cash Equivalents	1.4	0.83	3.61	5.24	7.95
Cash Growth	69.04%	-77.01%	-31.07%	-34.07%	833.73%
Receivables	0.01	0.01	0.02	0.02	0.01
Inventory	0	0.03	0.03	0.02	0.04
Other Current Assets	0.04	0.16	0.23	0.05	0.03
Total Current Assets	1.46	1.04	3.89	5.33	8.03
Property, Plant & Equipment	0.17	0.41	0.45	0.16	0.03
Other Long-Term Assets	0	0	0	0	0.02
Total Long-Term Assets	0.17	0.41	0.45	0.16	0.05
Total Assets	1.63	1.44	4.34	5.49	8.08
Accounts Payable	1.93	1.56	1.77	1.89	1.07
Current Debt	0.17	0.23	0.19	0.14	0
Total Current Liabilities	2.11	1.79	1.97	2.04	1.07
Long-Term Debt	0	0.16	0.23	0	0
Total Long-Term Liabilities	0	0.16	0.23	0	0
Total Liabilities	2.11	1.95	2.2	2.04	1.07
Total Debt	0.17	0.39	0.43	0.15	0
Debt Growth	-55.75%	-8.22%	189.80%	-	-
Retained Earnings	-199.14	-192.56	-180.03	-168.29	-155.11
Shareholders' Equity	-0.48	-0.51	2.15	3.45	7
Net Cash / Debt	1.23	0.44	3.19	5.09	7.95
Net Cash / Debt Growth	180.18%	-86.22%	-37.45%	-35.92%	833.73%
Net Cash Per Share	0.01	0.01	0.04	0.07	0.13
Working Capital	-0.65	-0.75	1.93	3.29	6.95
Book Value Per Share	-0.01	-0.01	0.03	0.05	0.12

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).